Trip Sitters & Psychedelic Guides in North Carolina
We Provide Trip Sitting & Guiding Services in Every Major City
- Charlotte
- Raleigh
- Greensboro
- Durham
- Winston-Salem
- Fayetteville
- Cary
- Wilmington
- High Point
- Concord
- Greenville
- Asheville
- Gastonia
- Jacksonville
- Chapel Hill
This list is not meant to be exhaustive. We provide our trip sitting and guiding services in all major cities in North Carolina, including those which are not listed above. If we can physically get ourselves to you, we will sit for you. If you are curious whether we are able to service your area specifically, please contact us.
Substances We Sit With
The one caveat to us being able to provide trip sitting and guiding services is that we cannot provide your substance of choice for personal consumption—we are unable to help with sourcing. Please understand that psychedelics are still federally controlled substances and you assume all the risk associated with possessing and consuming these medicines.
We are here to facilitate intentional psychedelic experiences where you feel supported along the entire journey—from preparation to sacred ceremonial experience to integration. We facilitate your inner healing by holding a safe, comfortable, non-judgmental space.
- Psilocybin
- Ayahuasca
- Mescaline
- Ketamine
- MDMA/MDA
- Cannabis
- DMT
- LSD
**Psychedelic Passage does not provide psychoactive or controlled substances nor are we licensed therapists, counselors, or medical professionals. We are a harm reduction company offering trip sitting & integration coaching services.**
Psychedelic Reform in North Carolina
We are in the midst of a psychedelic renaissance and the legal status of psychedelic substances is evolving rapidly. Though there are no current legislative reform initiatives for psychedelics in North Carolina, the state is home to promising research examining psychedelics as potential psychiatric treatments.
On June 16, 2020, The University of North Carolina School of Medicine announced a 4 year, $27M research partnership with the United States Defense Advanced Research Project Agency (DARPA). Led by Bryan L. Roth, MD, PhD, the program intends to research and develop new psychiatric medicines, including psychedelics. Though the word ‘psychedelics’ were not included in the press release, the statement did discuss certain Schedule 1 compounds that interact with serotonin receptors that may produce significant side effects, including hallucination.
The initiative’s first study discusses how psychedelics bind to key brain receptors and was published in Cell, a publisher of peer-reviewed scientific journals, in late 2020. We will continue to update this section as new developments arise.
